```html

Kaposi Sarcoma (Classic) – A Patient‑Friendly Guide

Overview

Kaposi sarcoma (KS) is a rare cancer that originates from the cells lining blood and lymphatic vessels (endothelial cells). The “classic” form most often affects older men of Mediterranean, Eastern European, or Middle‑Eastern descent and typically presents on the skin of the lower extremities. It is one of four epidemiologic variants of KS:

• Classic (also called “Mediterranean”) – the focus of this guide.
• AIDS‑related (epidemic) KS.
• Endemic (African) KS.
• Iatrogenic (transplant‑associated) KS.

Worldwide, classic KS accounts for roughly 5–10 % of all KS cases, with an estimated incidence of 0.03–0.05 per 100,000 persons per year in endemic regions.<sup>[1] Mayo Clinic</sup> The disease typically appears after the age of 60, is more common in men (male‑to‑female ratio ≈ 10:1), and often runs an indolent course.

Symptoms

Signs of classic KS are usually cutaneous, but internal involvement can occur. Common symptoms include:

Skin Lesions

• Macules or patches: flat, pink‑to‑red spots that may enlarge slowly.
• Papules and nodules: raised, violaceous or purple bumps, often firm to the touch.
• Ulcerated or necrotic lesions: advanced lesions can break down, bleed, or become painful.
• Distribution: typically on the lower legs, ankles, and feet; may spread to thighs, trunk, or oral mucosa.

Swelling (Lymphedema)

• Persistent swelling of the lower limbs caused by lymphatic obstruction from tumor infiltration.

Respiratory Symptoms

• When lesions involve the lungs, patients may experience a dry cough, shortness of breath, or hemoptysis (coughing up blood). This is less common in classic KS than in AIDS‑related disease.

Gastrointestinal (GI) Involvement

• Lesions in the stomach or intestines can cause abdominal pain, nausea, vomiting, or occult GI bleeding leading to anemia.

Systemic Signs

• Weight loss, fatigue, or low‑grade fever may indicate extensive disease, though they are not specific.

Causes and Risk Factors

Classic KS is strongly linked to infection with human herpesvirus‑8 (HHV‑8), also known as Kaposi sarcoma‑associated herpesvirus (KSHV). The virus integrates into endothelial cell DNA and triggers abnormal cell growth.

Key Risk Factors

• Age ≥ 60 years: the immune system naturally wanes with age, allowing HHV‑8 to reactivate.
• Male sex: hormonal and genetic factors may influence susceptibility.
• Mediterranean, Eastern European, or Middle‑Eastern ancestry: higher seroprevalence of HHV‑8 in these populations.
• HHV‑8 exposure: transmitted through saliva, sexual contact, and less commonly via blood or organ transplantation.
• Immunosuppression (non‑HIV): long‑term corticosteroids, chemotherapy, or solid‑organ transplantation increase risk.
• Family history: rare familial clustering suggests a genetic predisposition.

Unlike epidemic KS, classic KS is not directly caused by HIV infection, although co‑infection can accelerate disease.

Diagnosis

Diagnosis is a stepwise process that combines clinical evaluation with histopathology and imaging.

Clinical Examination

• Detailed skin inspection, measurement of lesion size, and assessment for edema.
• Oral cavity and genital examination to rule out mucosal lesions.

Biopsy

The definitive test. A punch or excisional biopsy of a representative lesion is examined under the microscope. Typical findings include:

• Spindle‑shaped endothelial cells forming slit‑like vascular spaces.
• Inflammatory infiltrate with plasma cells.
• Positive immunohistochemical staining for HHV‑8 latency‑associated nuclear antigen (LANA‑1).

Laboratory Tests

• Complete blood count (CBC) – to detect anemia from GI bleeding.
• Serology for HHV‑8 (optional, not routinely required for diagnosis).
• HIV testing – recommended to rule out co‑infection.

Imaging

• Chest X‑ray or CT scan: evaluates pulmonary involvement.
• Abdominal CT/MRI or endoscopy: assesses GI tract lesions when symptoms suggest.
• Ultrasound or Lymphoscintigraphy: helps quantify lymphedema and detect deep lymph node disease.

Staging

Staging systems (e.g., the AIDS Clinical Trials Group criteria adapted for classic KS) consider the extent of skin disease, edema, organ involvement, and systemic symptoms. Accurate staging guides therapeutic decisions.

Treatment Options

Management is individualized based on disease stage, lesion location, symptom burden, and patient comorbidities.

Observation (“Watchful Waiting”)

• Appropriate for solitary, asymptomatic lesions that are not function‑limiting.
• Regular follow‑up (every 3–6 months) to monitor for progression.

Local Therapies

• Surgical excision: curative for isolated nodules, especially on the lower leg.
• Intralesional chemotherapy: vincristine, bleomycin, or interferon‑α injected directly into lesions.
• Radiation therapy: low‑dose (20‑30 Gy) effective for painful or refractory cutaneous lesions.
• Cryotherapy or laser ablation: useful for small, superficial lesions.

Systemic Therapies

Indicated for multifocal disease, visceral involvement, or rapidly progressive lesions.

• Liposomal doxorubicin: first‑line chemotherapy with response rates ≈ 70 % in classic KS.<sup>[2] NCCN Guidelines</sup>
• Paclitaxel: alternative for patients intolerant to anthracyclines.
• Interferon‑α2a: antiviral and anti‑angiogenic; useful when immune competence is relatively preserved.
• Targeted agents: oral pomalidomide or lenalidomide (immunomodulatory) have shown activity in clinical trials.

Managing Lymphedema

• Compression stockings or multilayer bandaging.
• Manual lymphatic drainage performed by a certified therapist.
• Skin care to prevent cellulitis.

Supportive & Lifestyle Measures

• Smoking cessation – reduces vascular inflammation.
• Balanced diet rich in antioxidants to support immune health.
• Physical activity (e.g., walking, swimming) to improve circulation and lymphatic flow.

Living with Kaposi Sarcoma (Classic)

While classic KS is often slow‑growing, it can impact quality of life. Practical tips for daily management:

• Skin protection: apply sunscreen (SPF 30+) to lesions when outdoors; avoid trauma that could ulcerate nodules.
• Foot care: inspect feet daily for new lesions or signs of infection; keep nails trimmed.
• Compression therapy: wear properly fitted stockings to control edema; replace them every 6–12 months.
• Regular follow‑up: schedule dermatology/oncology visits at least twice a year, or more often if disease is active.
• Vaccinations: stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines to avoid secondary infections that could worsen immunosuppression.
• Psychosocial support: join support groups for patients with KS or rare cancers; consider counseling to address anxiety or body‑image concerns.
• Medication adherence: keep a medication calendar; discuss side‑effects promptly with your provider.

Prevention

Because HHV‑8 infection is lifelong, primary prevention focuses on reducing transmission and maintaining immune health.

• Limit salivary exposure: avoid sharing utensils, lip balm, or toothbrushes with individuals known to be HHV‑8 positive.
• Safe sexual practices: use condoms, especially with new partners; HHV‑8 can be sexually transmitted.
• Screen organ‑transplant candidates: HHV‑8 serology helps assess post‑transplant KS risk.
• Avoid unnecessary immunosuppression: discuss risks of long‑term steroids or biologics with your physician.
• Healthy lifestyle: balanced nutrition, regular exercise, adequate sleep, and stress management support overall immunity.

Complications

If left untreated or inadequately managed, classic KS can lead to:

• Severe lymphedema: chronic swelling predisposes to cellulitis, skin ulceration, and reduced mobility.
• Visceral organ failure: pulmonary or gastrointestinal involvement may cause respiratory insufficiency or chronic bleeding/anemia.
• Secondary infections: ulcerated lesions can become portals for bacterial entry.
• Psychological distress: visible skin lesions may affect self‑esteem and social functioning.
• Rare malignant transformation: long‑standing lesions can evolve into aggressive sarcomatous growth, though this is uncommon in the classic form.

When to Seek Emergency Care

References

1. Mayo Clinic. “Kaposi Sarcoma.” Updated 2023. https://www.mayoclinic.org
2. National Comprehensive Cancer Network (NCCN). “Clinical Practice Guidelines in Oncology: Kaposi Sarcoma.” Version 2.2024.
3. Centers for Disease Control and Prevention. “Human Herpesvirus 8 (HHV‑8) and Kaposi Sarcoma.” 2022. https://www.cdc.gov
4. World Health Organization. “WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues – 5th edition.” 2022.
5. Cleveland Clinic. “Kaposi Sarcoma.” 2023. https://my.clevelandclinic.org

```